Results 11 to 20 of about 2,285,924 (374)

Myelodysplastic syndromes

HemaSphere, 2019
Johanna Ungerstedt, (Coordinating Author)
doaj   +3 more sources

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

The Journal of the National Comprehensive Cancer Network, 2022
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and management of patients with MDS based on a review of clinical evidence that has led to important advances in treatment or has yielded new ...
P. Greenberg, R. Stone, A. Al-Kali, J. Bennett, U. Borate, A. Brunner, Wanxing Chai-Ho, P. Curtin, Carlos M. de Castro, H. Deeg, A. DeZern, S. Dinner, Charles E Foucar, K. Gaensler, G. Garcia-Manero, E. Griffiths, D. Head, B. Jonas, Siobán B. Keel, Y. Madanat, L. Maness, J. Mangan, Shannon R. McCurdy, C. McMahon, B. Patel, V. Reddy, D. Sallman, R. Shallis, P. Shami, Swapna Thota, A. Varshavsky-Yanovsky, P. Westervelt, Elizabeth M. Hollinger, Dorothy Shead, Cindy Hochstetler   +34 more
semanticscholar   +1 more source

The myelodysplastic syndromes [PDF]

Blood Reviews, 1987
The myelodysplastic syndromes constitute a fascinating model for monoclonal premalignant disorders. Haemopoiesis is 'dysplastic' with inefficient maturation of a slowly expanding or sometimes of a stable population, of blood cell precursors. About one third of the patients evolve into acute leukaemia, the result of either a progressive expansion of the
M.A. Boogaerts, R.L. Verwilghen
openaire   +6 more sources

Myelodysplastic syndromes

HemaSphere, 2018
Eva Hellström Lindberg
doaj   +2 more sources

Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

Journal of Clinical Oncology, 2021
PURPOSE Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication. METHODS We retrospectively enrolled 2,043
M. Bersanelli, E. Travaglino, M. Meggendorfer, Tommaso Matteuzzi, C. Sala, E. Mosca, C. Chiereghin, Noemi Di Nanni, Matteo Gnocchi, Matteo Zampini, M. Rossi, G. Maggioni, A. Termanini, E. Angelucci, M. Bernardi, L. Borin, B. Bruno, F. Bonifazi, V. Santini, A. Bacigalupo, M. Voso, E. Olíva, M. Riva, M. Ubezio, L. Morabito, Alessia Campagna, C. Saitta, V. Savevski, E. Giampieri, D. Remondini, F. Passamonti, F. Ciceri, N. Bolli, A. Rambaldi, W. Kern, S. Kordasti, F. Solé, L. Palomo, G. Sanz, A. Santoro, U. Platzbecker, P. Fenaux, L. Milanesi, T. Haferlach, G. Castellani, M. D. Della Porta   +45 more
semanticscholar   +1 more source

Myelodysplastic syndromes [PDF]

Seminars in Diagnostic Pathology, 2011
Myelodysplastic syndromes (MDS) are hematopoietic neoplasms characterized by an ineffective hematopoiesis associated with cytopenia(s), functional abnormalities of bone marrow lineages, morphologic dysplasia, and a progression to acute myeloid leukemia.
Jiehao, Zhou, Attilio, Orazi, Magdalena B, Czader   +2 more
openaire   +4 more sources

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

Leukemia, 2021
Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells.
Julia Stomper, J. Rotondo, G. Greve, M. Lübbert   +3 more
semanticscholar   +1 more source

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

New England Journal of Medicine, 2020
BACKGROUND Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions.
P. Fenaux, U. Platzbecker, G. Mufti, G. Garcia-Manero, R. Buckstein, V. Santini, M. Díez-Campelo, C. Finelli, M. Cazzola, O. Ilhan, M. Sekeres, J. Falantes, B. Arrizabalaga, F. Salvi, Valentina Giai, P. Vyas, D. Bowen, D. Selleslag, A. DeZern, J. Jurcic, U. Germing, K. Götze, B. Quesnel, O. Beyne-Rauzy, T. Cluzeau, M. Voso, D. Mazure, E. Vellenga, P. Greenberg, E. Hellström-Lindberg, A. Zeidan, L. Adès, A. Verma, M. Savona, A. Laadem, A. Benzohra, Jennie Zhang, A. Rampersad, D. Dunshee, P. Linde, M. Sherman, R. Komrokji, A. List   +42 more
semanticscholar   +1 more source

Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes

Blood Advances, 2018
: Anemia is the defining feature in most patients with myelodysplastic syndromes (MDS), yet defects in erythropoiesis have not been well characterized. We examined freshly obtained bone marrow (BM) samples for stage-specific abnormalities during terminal
Abdullah Mahmood Ali, Yumin Huang, Ronald Feitosa Pinheiro, Fumin Xue, Jingping Hu, Nicholas Iverson, Daniela Hoehn, Diego Coutinho, Jehanzeb Kayani, Brian Chernak, Joseph Lane, Christopher Hillyer, Naomi Galili, Joseph Jurcic, Narla Mohandas, Xiuli An, Azra Raza   +16 more
doaj   +1 more source

A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up. The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry [PDF]

, 2017
Data on Myelodysplastic Syndromes (MDS) are difficult to collect by cancer registries because of the lack of reporting and the use of different classifications of the disease.
Agabiti, Nera, Aloe Spiriti, Maria Antonietta, Andriani, Alessandro, Breccia, Massimo, Buccisano, Francesco, Cimino, Giuseppe, Criscuolo, Marianna, Davoli, Marina, De Fabritiis, Paolo, Faglioni, Laura, Fenu, Susanna, Fianchi, Luana, Gumenyuk, Svitlana, Latagliata, Roberto, Mancini, Stefano, Maurillo, Luca, Mayer, Flavia, Niscola, Pasquale, Nobile, Carolina, Piccioni, Anna Lina, Ricci, Roberto, Tafuri, Agostino, Tatarelli, Caterina, Trapã, Giulio, Voso, Maria Teresa, Zini, Gina   +25 more
core   +2 more sources